---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-25-000123"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:38:15.177699+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas Q2 net loss $53.2M; selects in vivo lead candidate in Sept; BMS CAR T milestone triggered

## Summary
- Q2 net loss $53.2M ($0.63/share) vs $67.6M loss a year ago; revenue $3.6M from BMS milestone.
- Cash $178.5M at June 30 (down from $269.9M at Dec 2024); runway into Q2 2027.
- R&D expense fell $38M to $16.2M on reni-cel discontinuation; restructuring charges $26.1M.
- First IND/CTA accepted for CD19 HD Allo CAR T with BMS, triggering milestone payment to Editas.
- On track to name lead in vivo candidate Sept 2025, file IND mid-2026, achieve POC by end 2026.

## SEC filing metadata
- accession: 0001650664-25-000123
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000123/0001650664-25-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000123/edit-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-25-000123
- JSON: https://secwatch.observer/filing/0001650664-25-000123.json
- Plain text: https://secwatch.observer/filing/0001650664-25-000123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.